Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 182.07B |
| Revenue (ttm) | 47.05B |
| Net Income (ttm) | 11.37B |
| Shares Out | 1.96B |
| EPS (ttm) | 5.64 |
| PE Ratio | 16.49 |
| Forward PE | 13.39 |
| Dividend | 3.50 (3.72%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 3,318,801 |
| Average Volume | 4,675,550 |
| Open | 94.78 |
| Previous Close | 94.21 |
| Day's Range | 92.81 - 96.29 |
| 52-Week Range | 81.10 - 102.72 |
| Beta | 0.53 |
| RSI | 50.19 |
| Earnings Date | Apr 29, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech SE (NASDAQ: BNTX) on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02 . The COVID-19 va...
BioNTech says Novartis executive Zapata-Gomez to become CFO
German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal
Key deals this week: Gold Fields, Palo Alto, Novartis, LendingClub and more
Final Trade: NVS, XLU and SMMT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: NVS, XLU and SMMT
The final trades of the day with CNBCs Melissa Lee and the Fast Money traders.
Regulus CVR may be worth $3-$4 a share in Novartis deal - analyst
Regulus Therapeutics (RGLS) sale to Novartis offers $7/share upfront & CVR worth $3-$4/share.
Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday. The Dow traded down 0.47% to 40,335.51 while the NASDAQ dipped 1.22% to 17,248.37. The S&P 500 ...
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis AG (NYSE: NVS) agreed to acquire Regulus Therapeutics Inc. (NASDAQ: RGLS) on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion . The upfront cash portion of the co...
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
Novartis: 2025 Guidance Raised To Top End Of Prior Range - Buy Confirmed
Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis
In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure...
Novartis to Acquire Regulus in $1.7 Billion Deal
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.
Novartis to acquire Regulus for $7.00 a share in cash
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutic...
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximate...
We have put ourselves in the right position to manage tariffs: Novartis CEO
Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings.
We have put ourselves in the right position to manage tariffs: Novartis CEO
Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings.
Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry
Vasant Narasimhan, Novartis CEO, discusses the impact of potential tariffs.
Novartis AG (NVS) Q1 2025 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - CEO Harry Kirsch - CFO Conference Ca...
Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance
Novartis AG (NYSE: NVS) reported first-quarter 2025 adjusted earnings per share of $2.28, beating the street view of $2.10 . Quarterly sales of $13.23 billion marginally outpaced the analyst consensu...